Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Wells Fargo & Company

Analysts at Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report issued on Friday,Benzinga reports. The brokerage set an “overweight” rating and a $115.00 price target on the biotechnology company’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 128.58% from the company’s current price.

Several other analysts also recently issued reports on SRPT. Cantor Fitzgerald restated an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $161.00 to $87.00 in a report on Monday, March 31st. HC Wainwright raised shares of Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price objective for the company in a research note on Wednesday, April 2nd. Needham & Company LLC lowered their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd. Finally, Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $161.09.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $50.31 on Friday. The stock’s fifty day simple moving average is $89.37 and its 200 day simple moving average is $110.71. The stock has a market capitalization of $4.88 billion, a price-to-earnings ratio of 40.25 and a beta of 0.93. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52-week low of $48.01 and a 52-week high of $173.25.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently bought and sold shares of SRPT. Captrust Financial Advisors increased its holdings in shares of Sarepta Therapeutics by 15.2% during the 3rd quarter. Captrust Financial Advisors now owns 3,871 shares of the biotechnology company’s stock valued at $483,000 after acquiring an additional 511 shares during the last quarter. Stifel Financial Corp boosted its position in Sarepta Therapeutics by 99.3% during the third quarter. Stifel Financial Corp now owns 37,207 shares of the biotechnology company’s stock worth $4,647,000 after purchasing an additional 18,537 shares during the period. Kovitz Investment Group Partners LLC grew its holdings in Sarepta Therapeutics by 36.7% during the third quarter. Kovitz Investment Group Partners LLC now owns 2,814 shares of the biotechnology company’s stock valued at $322,000 after purchasing an additional 755 shares during the last quarter. M&T Bank Corp raised its position in shares of Sarepta Therapeutics by 8.5% in the third quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 349 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after buying an additional 44,306 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.